Search

Your search keyword '"Wang, Cunshan"' showing total 296 results
Start Over Author "Wang, Cunshan"
296 results on '"Wang, Cunshan"'

57. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study

Author

Deodhar, Atul, primary, Sliwinska-Stanczyk, Paula, additional, Xu, Huji, additional, Baraliakos, Xenofon, additional, Gensler, Lianne S, additional, Fleishaker, Dona, additional, Wang, Lisy, additional, Wu, Joseph, additional, Menon, Sujatha, additional, Wang, Cunshan, additional, Dina, Oluwaseyi, additional, Fallon, Lara, additional, Kanik, Keith S, additional, and van der Heijde, Désirée, additional

Published
2021
Full Text
View/download PDF

67. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data

Author

Mease, Philip, primary, Charles-Schoeman, Christina, additional, Cohen, Stanley, additional, Fallon, Lara, additional, Woolcott, John, additional, Yun, Huifeng, additional, Kremer, Joel, additional, Greenberg, Jeffrey, additional, Malley, Wendi, additional, Onofrei, Alina, additional, Kanik, Keith S, additional, Graham, Daniela, additional, Wang, Cunshan, additional, Connell, Carol, additional, Valdez, Hernan, additional, Hauben, Manfred, additional, Hung, Eric, additional, Madsen, Ann, additional, Jones, Thomas V, additional, and Curtis, Jeffrey R, additional

Published
2020
Full Text
View/download PDF

71. Changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis: a pooled analysis acrossphase III and long‐term extension studies

Author

Gladman, Dafna D., Charles‐Schoeman, Christina, McInnes, Iain B., Veale, Douglas J., Thiers, Bruce, Nurmohamed, Mike, Graham, Dani, Wang, Cunshan, Jones, Thomas, Wolk, Robert, and DeMasi, Ryan

Abstract

Objective:\ud \ud The risk of cardiovascular disease (CVD) is higher in patients with psoriatic arthritis (PsA) compared to the general population. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Because tofacitinib increases circulating lipid levels in some patients, we evaluated CVD risk factors and major adverse cardiovascular events (MACE) in patients with active PsA receiving tofacitinib 5 or 10 mg twice daily plus conventional synthetic disease‐modifying antirheumatic drugs.\ud Methods:\ud \ud Data were pooled from 2 phase III studies (Efficacy and Safety of Tofacitinib in Psoriatic Arthritis [OPAL Broaden] and Tofacitinib in Patients with Psoriatic Arthritis With Inadequate Response to TNF Inhibitors [OPAL Beyond]) and 1 ongoing long‐term extension (Open‐Label Extension Study of Tofacitinib in Psoriatic Arthritis [OPAL Balance], data cutoff January 2017; database not locked). Outcomes included fasting lipid levels, blood pressure, hypertension‐related adverse events (AEs; including hypertension, high blood pressure, and increased blood pressure), and MACE.\ud Results:\ud \ud Overall, 783 tofacitinib‐treated patients were included. Percentage increases from baseline in low‐density lipoprotein cholesterol (LDL‐c) and high‐density lipoprotein cholesterol (HDL‐c) levels ranged from 9% to 14% for tofacitinib 5 mg and 10 mg at 3 and 6 months; no meaningful changes in LDL‐c:HDL‐c or total cholesterol:HDL‐c ratios were observed. Blood pressure remained stable for 24 months. Fifty‐eight patients (7.4%) had hypertension‐related AEs; none were fatal (incidence rate [IR] per 100 patient‐years 4.81 [95% confidence interval (95% CI) 3.65–6.22]). Five patients (0.6%) had MACE (IR 0.24 [95% CI 0.05–0.70]); 2 were fatal.\ud Conclusion:\ud \ud Serum lipid level increases at month 3 following tofacitinib treatment in PsA were consistent with observations in rheumatoid arthritis and psoriasis. The IR of hypertension‐related AEs and MACE was low; long‐term follow‐up is ongoing.

Published
2019

73. 铝含量对激光增材制造TC4合金组织及性能的调控

Author

葛禄成 Ge Lucheng, 赵紫松 Zhao Zisong, 刘宁夏 Liu Ningxia, 梁彦鹏 Liang Yanpeng, 张静涛 Zhang Jingtao, and 王存山 Wang Cunshan

Subjects
Electrical and Electronic Engineering, Atomic and Molecular Physics, and Optics, Electronic, Optical and Magnetic Materials
Published
2021

74. Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long‐Term Extension Studies

Author

Gladman, Dafna D., primary, Charles‐Schoeman, Christina, additional, McInnes, Iain B., additional, Veale, Douglas J., additional, Thiers, Bruce, additional, Nurmohamed, Mike, additional, Graham, Dani, additional, Wang, Cunshan, additional, Jones, Thomas, additional, Wolk, Robert, additional, and DeMasi, Ryan, additional

Published
2019
Full Text
View/download PDF

81. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs

Author

Strand, Vibeke, primary, de Vlam, Kurt, additional, Covarrubias-Cobos, Jose A, additional, Mease, Philip J, additional, Gladman, Dafna D, additional, Graham, Daniela, additional, Wang, Cunshan, additional, Cappelleri, Joseph C, additional, Hendrikx, Thijs, additional, and Hsu, Ming-Ann, additional

Published
2019
Full Text
View/download PDF

86. Analysis of the Microstructure of Laser Melting Layer on Mg Alloy

Author

张海波 Zhang Haibo, 王存山 Wang Cunshan, 接勐 Jie Meng, and 高亚丽 Gao Yali

Subjects
Materials science, law, Alloy, Metallurgy, engineering, Melting layer, engineering.material, Electrical and Electronic Engineering, Microstructure, Laser, law.invention
Published
2013

92. Composition Design and Properties of Laser Clad Ni-Zr-Al Alloy Coating on the Magnesium Surface

Author

李婷 Li Ting, 王存山 Wang Cunshan, 陈永哲 Chen Yongzhe, and 姚标 Yao Biao

Subjects
Materials science, Magnesium, Metallurgy, chemistry.chemical_element, Laser, Atomic and Molecular Physics, and Optics, Electronic, Optical and Magnetic Materials, law.invention, chemistry, law, 5052 aluminium alloy, Composition (visual arts), Electrical and Electronic Engineering, Alloy coating
Published
2009

96. Systemic Tofacitinib Concentrations in Adult Patients With Atopic Dermatitis Treated With 2% Tofacitinib Ointment and Application to Pediatric Study Planning.

Author

Purohit, Vivek S., Ports, William C., Wang, Cunshan, and Riley, Steve

Subjects
ATOPIC dermatitis treatment, ALLOMETRY, NEUROTRANSMITTER uptake inhibitors, STATISTICAL sampling, BLIND experiment, JANUS kinases, PHARMACODYNAMICS, THERAPEUTICS
Abstract

Atopic dermatitis is a chronic eczematous, pruritic, inflammatory skin condition affecting children and adults. Tofacitinib is a Janus kinase inhibitor. The efficacy, safety, and pharmacokinetics of 2% tofacitinib ointment twice daily have been evaluated in a 4‐week phase 2a multisite randomized, double‐blind, vehicle‐controlled, parallel‐group study (NCT02001181) in adult patients with mild to moderate atopic dermatitis and 2% to 20% body surface area (BSA) involvement. Tofacitinib ointment demonstrated significantly greater efficacy versus vehicle for all efficacy end points and had an acceptable safety profile. Predose and postdose pharmacokinetic samples were collected in week 2 and week 4. The objective of this analysis was to assess if predicted mean tofacitinib concentrations with topical application at higher treated BSA across age groups would exceed relevant concentration thresholds based on oral doses of tofacitinib. In this analysis, the pharmacokinetic concentrations were characterized using a linear mixed‐effects model. The model was used to predict concentrations for adults with higher (>20%) treatable BSA. Adult concentrations were used to extrapolate concentrations to a pediatric population (2 to 17 years) using allometric principles. The predicted systemic concentrations for 2% tofacitinib ointment in both adult and pediatric populations at treated BSA ≤50% for a mild to moderate atopic dermatitis population did not exceed those reported for the 10th percentile of observed oral tofacitinib 5‐mg twice‐daily doses in patients with moderate to severe plaque psoriasis. The methodology described will enable analysis and prediction of systemic concentrations for topical agents. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

98. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial

Author

Papp, Kim A., primary, Bissonnette, Robert, additional, Gooderham, Melinda, additional, Feldman, Steven R., additional, Iversen, Lars, additional, Soung, Jennifer, additional, Draelos, Zoe, additional, Mamolo, Carla, additional, Purohit, Vivek, additional, Wang, Cunshan, additional, and Ports, William C., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results